Background. Guidelines have set goals for risk factor management in chronic kidney disease (CKD) patients. These goals are often not met. In this analysis, we set out to assess the quality of risk factor management in CKD and to identify factors that determine the quality of care (QoC). For that purpose, baseline data of the MAS-TERPLAN (Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of Nurse practitioners) study have been used. MASTERPLAN is a multicentre study which evaluates the effect of a multifactorial intervention in prevalent CKD patients on cardiovascular (CV) events and progression of kidney failure. Methods. QoC was quantified using a score based on the number of 11 defined treatment goals on target. The maximum score per patient was 11. Results. The average (±SD) QoC score was 6.7 (±1.5). The average score per centre ranged from 5.9 to 6.9. In a multivariable analysis, centre proved to be a significant, independent determinant of QoC with a difference up to 0.7 between centres. This difference remained when adjustments were made for those risk factors primarily treated by pharmacotherapy. Other factors that were significantly related to the QoC were estimated glomerular filtration rate, Caucasian race, diabetes mellitus, diabetic nephropathy as cause of kidney disease and previous kidney transplantation. Conclusions. In CKD patients, risk factors for progression of kidney failure and CV events were inadequately controlled. Treatment centre proved to be an important determinant of QoC. This data may point towards the physician's interest and preference as important determinants of QoC. This is a potentially modifiable determinant of the quality of patient care [Trial registration ISRCTN registry: 73187232 (http://isrctn.org)].
Introduction
Management of chronic diseases such as diabetes, hypertension and chronic kidney disease (CKD) is difficult. For all these disease conditions, treatment guidelines are defined, but treatment goals are often not achieved. Identifying factors predictive for the quality of the prescribed and the achieved care may help to improve the overall quality of care (QoC). We had the opportunity to study this in some detail in a group of CKD patients.
The guidelines for treatment of CKD patients aim to reduce the risk of progression of kidney failure and of cardiovascular (CV) morbidity and mortality [1] [2] [3] [4] [5] [6] . The risk factor profile includes factors targetable by pharmacological intervention and by lifestyle changes. However, in patients with CKD, as well as in other patient groups, treatment goals are often not met [7] [8] [9] . Various factors have been suggested as contributing factors, including patient characteristics (gender, age and comorbidity), hospital characteristics (teaching versus non teaching, profit versus non-profit), regional or country specific aspects and physician's preferences and interest [9] [10] [11] . Since detailed information on these issues is not available, we set out to study the quality of risk factor management in patients with CKD and to identify factors that may determine QoC. In that respect, we were particularly interested in risk factors accessible for improvement. We used the baseline data of the MASTERPLAN (Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of Nurse practitioners) study, a randomized, controlled multicentre study evaluating the added value of nurse practitioner care in reducing CV events and attenuating the decline of kidney function in patients with prevalent CKD.
Materials and methods

MASTERPLAN study
The MASTERPLAN study is a randomized controlled trial conducted in nine centres with a nephrology department in the Netherlands. Rationale and design have been published elsewhere [12, 13] . Ethics committee approval was obtained as well as written informed consent of all participants.
In brief, adult patients with moderate or severe CKD [estimated glomerular filtration rate (eGFR) by Cockcroft-Gault equation between 20 and 70 mL/min] seen in an outpatient clinic by a nephrologist or general internist were included. All participating hospitals were teaching hospitals that offered a full range of nephrology treatment including kidney replacement therapy (both haemodialysis and peritoneal dialysis) and were involved in the care of kidney transplant recipients. Three centres were university clinics that offered tertiary care and had kidney transplant programmes. The number of beds per hospital ranges from 414 to 953. The six non-university clinics comprise 14% of the 43 Dutch hospitals with a full nephrology service in the Netherlands in 2004. The three university clinics represent 38% of eight university clinics in the Netherlands.
Patient evaluation
Baseline measurements consisted of a questionnaire recording smoking behaviour, physical activity and medication use. Physical examination consisted of measurement of height, weight and blood pressure (oscillometric blood pressure measurements after 15 min of supine rest, mean of five measurements in the following 15 min). Blood was drawn and a 24-h urine sample was collected. Blood and urine samples were analysed by the laboratory of the centre. Medical history was obtained from the medical records. History of CV disease was defined as a history of myocardial infarction, stroke or vascular intervention. Diabetes mellitus (DM) was defined as the use of glucose-lowering drugs or a fasting glucose >126 mg/dL (7.0 mmol/L). Adherence to the Dutch guidelines of healthy physical exercise was determined with the validated Short Questionnaire to Assess Health (SQUASH) questionnaire [14] . The underlying diagnosis of kidney disease was determined by the treating physician and categorized using the ERA (European Renal Association)-EDTA (European Dialysis and Transplant Association) registration criteria. Income was estimated from postal code area based upon data of Statistics Netherlands [15] . Presently, the modification of diet in renal disease (MDRD) formula is well accepted. To allow comparisons with other studies, we report eGFR using the abbreviated MDRD formula [16] .
Data analysis
Baseline characteristics were given for the study population by participating centre and expressed as mean (SD) or proportions. Differences between centres in risk factors were studied using analysis of variance adjusted for age and gender if applicable. Mann-Whitney U test was used when comparing two groups. For risk factors primarily treated by pharmacotherapy, the presence of treatment was assessed. With regard to missing cases, two analyses were performed: an analysis without cases with missing values was performed and an analysis in which missing data were imputed. The presented data are after imputation.
QoC score
Based on guidelines available at the time of inclusion (2004), 11 treatment goals proven or very likely associated with CV risk and risk of progression of kidney failure were defined as shown in Table 1 . Achievement of a particular treatment goal was credited by 1 point. Thus, to each participant a maximal score of 11 points could be given. Quality of risk factor management was quantified as an unweighted summation of the score for these 11 goals. The calculated QoC score thus ranges from zero to 11.
An additional score was constructed which incorporated only the risk factors primarily treated by pharmacotherapy (Table 1 ). This score was also unweighted and had a maximum of 7 points. Treatment for the different components of the QoC was defined as any drug specifically prescribed to treat this disorder. For proteinuria and blood pressure (BP), any use of any antihypertensive medication was considered treatment.
Determinants of QoC
Factors related to QoC were studied using univariable linear regression models. The factors evaluated were age, gender, race, prior CV disease, presence of DM, previous kidney transplant, eGFR, primary nephrological diagnosis (using congenital kidney disease as a reference) and treatment centre. Centre E was used as reference; this was the lowest ranked centre with regard to unadjusted QoC score (Appendix A).
Determinants that showed a univariable relationship with the QoC score with a P-value < 0.157 were entered in the multivariable linear regression model. This value is derived from prognostic modelling [17] . Since patients are clustered within hospitals and this might affect associations between QoC and its determinants, we applied generalized estimating equations (GEE) to correct for this clustering [18] . The analysis was done with SAS v9.1 (SAS Institute Inc., Cary, USA). Possible confoun- ders [hospital size, academic status, number of visits in the year prior to randomization, duration of follow-up by a nephrologist or internist prior to inclusion (this was recorded using the dates of the visits in the year prior to inclusion)] were studied separately in univariable and the constructed multivariable model.
Centre performance with individual risk factors
Performance of the different centres with regard to the defined 11 risk factors was plotted. The performance of centres was evluated in a model adjusted for age, gender, cause of kidney disease, monthly income, kidney function, race and a history of kidney transplantation. Centres were also ranked by their adjusted QoC scores and by the adjusted QoC scores for the risk factors primarily treated by pharmacotherapy, to allow for easy comparison of both scores.
Results
Between April 2004 and December 2005, 793 prevalent patients were enrolled (65-105 patients/centre). Five patients did not meet inclusion criteria (n = 3) or declined participation after randomization (n = 2). Data of 788 patients were available for analysis. These patients had been under medical specialist care for a median of 308 days (interquartile range = 233-361 days). Baseline characteristics of the entire cohort are presented in Table 2 . There were significant differences in baseline characteristics between centres for all parameters except for prior CV disease, history of DM, estimated income, proteinuria, smoking and adherence to guidelines of physical activity (see Appendix A). Data on serum parathyroid hormone (PTH) levels, proteinuria and sodium in urine were unavailable in, respectively, 4.1, 5.3 and 8.5% of patients. No difference was seen between centres in the availability of data. Table 3 describes the overall performance for the individual treatment goals and their relation with pharmacotherapy. The percentage of patients on goal ranged from 17 to 92%. When considering achievement of treatment goals, haemoglobin ranked highest and urinary sodium excretion lowest. Thirty-seven percent of patients had adequately controlled blood pressure. Four percent of patients with inadequately controlled blood pressure were untreated, whereas 45 and 72% of patients with increased levels of low density lipoprotein (LDL) cholesterol and PTH were untreated.
QoC
The mean QoC score for the entire cohort was 6.7 (±1.5) ( Table 2 ). For the individual centres, the mean score ranged from 5.9 to 6.9 (Appendix A). Only in 1.5% of patients was a score of 10 or 11 found ( Figure 1A) . In 70% of patients a score of 7 or less was found.
The mean score for risk factors primarily treated by pharmacotherapy was 4.8 (±1.1) ( Figure 1B ). Table 4 shows univariable and multivariable changes in QoC associated with a one unit change of the determinant. A negative regression coefficient is associated with a decline in QoC, and a positive regression coefficient is Values given as n (%). BP, blood pressure; PTH, parathyroid hormone; uNA, urinary sodium excretion; BMI, body mass index.
Determinants of QoC
Quality of care in patients with CKD is determined by hospital specific factors 3649 associated with a rise in QoC. Kidney transplant recipients tended to have a lower QoC score, as did patients with a history of DM, patients with diabetic nephropathy or renovascular disease (Table 4 ). Higher eGFR, higher monthly income and Caucasian race were associated with a higher QoC score. As compared to centre E, other centres showed a significantly higher QoC in univariable analyses ( Table 4) . The difference between centres persisted in GEE analysis with adjustment for the mentioned determinants and additionally age and gender (Table 4 ). The differences between treatment centres could not be explained by differences between the centre size [number of beds/centre (P = 0.20)], the number of visits per patient in the year prior to randomization (P = 0.19), the time a patient was seen by an internist or nephrologist prior to inclusion (P = 0.18) or setting [university clinic versus non-university clinic (P = 0.82)]. In additional analyses, we observed that the QoC score was negatively associated with the number of drugs per patient. The QoC score decreased by 0.13 per drug added (P < 0.001). However, addition of this variable in the multivariable model shown in Table 4 did not alter the results of our analysis (data not shown). We performed similar analyses using a QoC score based on risk factors that are primarily treated by pharmacotherapy. Firstly, a ranking was performed based upon an adjusted calculated score for both QoC scores (Table 5 ). In general, the ranking seems more or less comparable for both scores, with the exception of centres C, E and F (Table 5) .
In the multivariable analysis, additional adjustment was made for lifestyle-associated risk factors (GEE Model 2, Table 5 ). Differences between centres were not influenced by this additional adjustment.
Centre performance with individual risk factors Figure 2 illustrates the QoC in the centres for the individual treatment parameters, expressed as the percentage of patients that achieved the target. The absolute difference between the best and worst performing centre based on the baseline data of the study for a risk factor ranges from 14% for smoking (on target range 72-86%) to 50% for PTH (on target range 30-80%). The mean difference for lifestyle modifiable risk factors [smoking, body mass index (BMI), urinary sodium excretion, physical activity] was 19% versus a mean difference of 32% for pharmacotherapy modifiable risk factors (BP, proteinuria, phosphate, PTH, Hba1c, Hb) (P = 0.04).
Logistic regression with adjustment for age, gender, race, history of CV disease, cause of kidney disease, prior kidney transplantation, history of DM and eGFR showed significant differences between centres (P < 0.02) for phosphate, haemoglobin, Hba1c, PTH, LDL cholesterol, blood pressure, BMI and urinary sodium excretion; no significant differences were observed for proteinuria, physical activity and smoking.
The same figure with every centre recognizable by a different colour is available online (Appendix B). This demonstrated large heterogeneity, i.e. each centre performed well for some risk factors and not so well for others.
Discussion
Our study clearly indicated that in a considerable percentage of patients with mild to moderate CKD, treatment goals aimed at reducing risk of kidney failure progression and reducing CV morbidity were not achieved. This conclusion held for risk factors related to lifestyle and to pharmacotherapy. Importantly, there were differences between the centres that persisted after adjustment for a variety of determinants including differences in patient mix between centres. Therefore, this finding may point to centre-specific causes that need further study in order to improve the QoC.
QoC
Based upon the QoC score ( Figure 1A ) and the performance with individual risk factors (Figure 2) , it was evident that treatment goals were very often not achieved in Fig. 1. (A) . Distribution of quality of care (QoC) score, expressed as the sum of the achieved individual treatment goals for the entire study population. Eleven treatment goals were identified. The maximal score is 11. (B). Distribution of the QoC score based on seven risk factors that are primarily treated by pharmacotherapy (see Table 1 for risk factors). this cohort. Our data are in line with previous studies in patients with CKD, which all showed an inadequate control of risk factors in patients with CKD (Appendix C) [7] [8] [9] . Moreover, when comparing these studies, it is clear that despite the recent introduction of guidelines on risk factor management in patients with CKD, there was only 140/80 mm Hg and the mean value in our study was 135/ 78 mm Hg [7, 8] . Admittedly, this might be explained by a difference in methods of blood pressure assessment (office blood pressure in previous studies versus automated device in our study) in risk factor management between countries and more strict treatment goals in newer guidelines [9, 11, 19] . We observed a large variation in the quality of control of risk factors that are treatable by pharmacotherapy, i.e. blood pressure, lipids and PTH (Figure 2 ). Whereas most patients received some form of antihypertensive treatment, many patients with inadequately controlled cholesterol and PTH levels were untreated. Similar observations have been made by Tonelli et al.: patients with CKD were less likely to receive pharmacotherapy for dyslipidaemia or anaemia, whereas most were treated for high blood pressure [7] .
Determinants of QoC
Several patient-related factors were related to the level of QoC. Our findings that a decline in kidney function was related to a lower QoC score were in agreement with others and have several explanations [7, 8] . It could be attributed to the fact that some risk factors occurred during the course of kidney failure progression and were not apparent in the early stages of CKD (for instance anaemia and hyperphosphataemia) [8] . Secondly, some risk factors become more difficult to control as kidney failure progresses (for instance blood pressure). Furthermore, literature data suggest that in CKD the physician's focus may be predominantly on risk factors for kidney disease progression (hypertension, proteinuria), with less attention for CV risk factors such as cholesterol [7] . We confirmed this observation: more patients received pharmacotherapy for hypertension than for dyslipidaemia in our cohort.
In agreement with other studies, diabetic nephropathy, gender and race were associated with a worse control of risk factors [20, 21] . In our study, age, a variable predictive in studies in coronary heart disease patients, was not associated with QoC [21, 22] .
An additional observation which should be addressed is the apparent paradoxical relation between number of prescribed drugs and QoC score. It is counterintuitive that more drugs are associated with less achievement of treatment goals. We interpret this finding as a confounder: confounding by indication in particular. The worse controlled patient was prescribed more drugs in an effort to improve outcome. In the absence of achieving the treatment goal, this will result in the association established in our cohort.
Possibly the most important finding of our analysis was that treatment centre was an independent and considerable determinant of QoC. The multivariable-adjusted difference between the highest and lowest ranking centre in the number of risk factors not on target was as high as 0.75. To put this into perspective, the same difference existed between patients with an eGFR of 30 and 60 mL/min/1.73 m 2 , respectively. A difference that was clearly associated with an increase of CV risk [23] . Few data are available on differences in the QoC between countries, between regions and between hospitals [9] [10] [11] . Differences have partly been attributed to the size of the hospital, the role of the hospital as a teaching hospital and to some financial incentives. We were not able to confirm these findings.
It was not clear which factors may explain the observed differences. Obviously, we could not exclude that undetermined patient characteristics, such as (un)employment or social economic status, were important. Generally, patients with low education and socio-economic status are more likely to have lower scores on lifestyle modifiable factors [24] . In these patients, undertreatment is suspected to be caused by the inability to pay for the additional costs of medication. In the Netherlands, all patients have health care insurance and receive (most of) the prescribed medication free of charge. There is also no difference in the availability of care for patients based upon socio-economic factors or type of insurance. All hospitals in the Dutch healthcare system are equally accessible for all patients. Moreover, our analysis showed that all centres perform more or less equal for lifestyle factors. The most important differences between centres concerned pharmacotherapy modifiable risk factors. This suggests not only that socio-economic status is not a major factor but also that improvement of QoC is indeed feasible. This finding was supported by the fact that additional adjustment for lifestyle factors (smoking, urinary sodium excretion, BMI and physical activity) in the model for QoC score based on risk factors that were primarily treated by pharmacotherapy did not markedly affect the differences between centres.
This suggested that not only unmeasured patient characteristics but also treatment-related factors might explain the observed centre difference. It was also evident that the difference between the centres was not the result of overall variation in performance of the physicians that take care of the patients. Performance for one risk factor was not related to performance in another factor. The observation that the differences in quality of control were larger for pharmacotherapy modifiable risk factors than for lifestyle Fig. 2 . Performance of nine centres in 11 risk factors. In the figure for every risk factor per centre, the percentage of patients achieving the treatment goal is depicted after adjustment for age, gender, race, history of CV disease, cause of kidney disease, prior kidney transplantation, history of diabetes mellitus, monthly income and eGFR. Phos, serum phosphorus; Hb, haemoglobin; Prot, proteinuria; DM, diabetes mellitus; PTH, parathyroid hormone; LDL, LDL cholesterol; BP, blood pressure; Act, physical activity; BMI, body mass index; uNa, urinary sodium excretion; Smo, smoking.
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modifiable risk factors supported the idea of real treatment differences between centres. We could only speculate what explains the unexpected differences between centres. There may be differences between physicians in their choice of target, some putting more emphasis on regulating blood pressure, others focusing on phosphorus and PTH. There may be a difference in therapeutic inertia (i.e. the tendency not to adjust the intensity of treatment, despite the fact that a certain risk factor does not meet the treatment goal). Also differences in therapeutic strategy may be involved. For instance, drug dosing or the combination of certain drugs (e.g. antihypertensives) might affect the number of treatment goals on target. Future research taking into account aforementioned aspects of treatment should identify the causes of these differences.
Limitations of the analysis
The current analysis has several limitations. This analysis was performed using the baseline data of patients who were included in a prospective randomized trial. Information on non-participating patients who fulfilled the inclusion criteria was lacking, therefore we could not exclude that the differences between centres are partly explained by differences in their selection of patients.
The observed difference between centres was an unexpected finding; therefore we also lacked information on the attitude of the physicians with respect to guidelines and the defined treatment targets. Information on dosage of drugs was not included in our data analysis.
In our analysis, we constructed a score in which every risk factor had the same weight. One could argue that a weighted score taking into account the size of contribution to CV risk would result in a more meaningful score. However, currently there are virtually no data to estimate these risks accurately. Therefore, we decided not to add weight to the different risk factors. Additionally, the role of every separate risk factor in the score could be questioned. The current score is composed of risk factors which are extensively addressed in international guidelines primarily focused at the reduction of CV events and consolidation of kidney function and therefore comprise a good overview of targets of treatment in patients with CKD. Particularly lipid lowering therapy might be considered debatable. At the time of the start of the study, major lipid lowering trials in dialysis patients, however,
were not yet published [25, 26] . Moreover, the available data supported the hypothesis of CV protection of statins in CKD [27] . However, the score has not been validated in prospective studies and still has to prove its value with regard to hard endpoints like myocardial infarction, death or kidney disease progression.
Ideally, QoC should only take into account patients who originally had abnormal values. In that case, analysis of a change over time more adequately reflected the performance of the centre or physician. The present cross-sectional study did not allow such an analysis.
It is important to realize that we reported on a Dutch population primarily under the care of nephrologists. This notion did not affect the established centre-effect but might affect the generalizability of the findings. This may have had two consequences. Firstly, patients under the care of a nephrologist are a different population than patients under the care of an internist or general practitioner. It is likely that more polycystic kidney disease and glomerulonephritis are present in this group. Furthermore, diabetes is less prevalent in the Dutch general and dialysis population compared to other countries and therefore it is likely that this also holds for the CKD population [28, 29] .
Conclusion
In CKD patients, risk factors for kidney failure progression and CV morbidity and mortality were inadequately controlled. Many patients did not receive appropriate pharmacotherapy, indicating that QoC can be improved. Treatment centre proved to be an important determinant of the QoC score. The difference between centres was not explained by patient characteristics or readily identifiable hospital characteristics. There was no uniform ranking of hospitals when considering the individual risk factors. These data suggest that physician's interest and preference may be important determinants of QoC. This is a potentially modifiable determinant of the quality of patient care.
